Key Points
- GSK insider Emma Walmsley purchased 7 shares of GSK stock at an average price of GBX 1,641 per share, totaling £114.87, marking her continued investment in the company.
- GSK's stock opened at GBX 1,625, with a one-year range of GBX 1,242.50 to GBX 1,684.50, and it currently holds a market cap of £65.40 billion.
- Analysts have mixed views on GSK, with a consensus rating of "Hold" and varying price targets, including a high of GBX 2,100 from Shore Capital and a low of GBX 1,450 from Deutsche Bank.
GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley purchased 7 shares of GSK stock in a transaction on Thursday, October 9th. The stock was bought at an average cost of GBX 1,641 per share, for a total transaction of £114.87.
Emma Walmsley also recently made the following trade(s):
- On Tuesday, September 9th, Emma Walmsley acquired 9 shares of GSK stock. The stock was acquired at an average price of GBX 1,486 per share, for a total transaction of £133.74.
- On Monday, August 11th, Emma Walmsley acquired 9 shares of GSK stock. The stock was acquired at an average price of GBX 1,408 per share, for a total transaction of £126.72.
GSK Trading Down 0.9%
GSK opened at GBX 1,625 on Friday. GSK plc has a one year low of GBX 1,242.50 and a one year high of GBX 1,684.50. The company has a market cap of £65.40 billion, a P/E ratio of 1,964.93, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The business's 50-day simple moving average is GBX 1,488.36 and its 200-day simple moving average is GBX 1,439.31.
GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts expect that GSK plc will post 175.980975 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently commented on the company. Berenberg Bank reiterated a "hold" rating and issued a GBX 1,600 price objective on shares of GSK in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 1,450 price objective on shares of GSK in a report on Thursday, July 31st. Shore Capital restated a "buy" rating and set a GBX 2,100 price target on shares of GSK in a research note on Wednesday, August 27th. Finally, JPMorgan Chase & Co. restated an "under review" rating on shares of GSK in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of GBX 1,637.50.
Get Our Latest Research Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
